Mangalam Drugs & Organics Limited (MANGALAM.BO)
INR 75.87
(4.16%)
INR 75.87
(4.16%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -90.71 Million INR | -814.31% |
| 2022 | 12.7 Million INR | -93.54% |
| 2021 | 196.57 Million INR | -29.72% |
| 2020 | 279.7 Million INR | 238.94% |
| 2019 | 82.52 Million INR | 202.76% |
| 2018 | -80.3 Million INR | -140.38% |
| 2017 | 198.89 Million INR | -10.71% |
| 2016 | 222.75 Million INR | 38.93% |
| 2015 | 160.33 Million INR | 161.07% |
| 2014 | 61.41 Million INR | 302.07% |
| 2013 | -30.39 Million INR | 74.24% |
| 2012 | -117.99 Million INR | -1962.28% |
| 2011 | 6.33 Million INR | -69.66% |
| 2010 | 20.88 Million INR | 14.56% |
| 2009 | 18.23 Million INR | 43.72% |
| 2008 | 12.68 Million INR | 47.88% |
| 2007 | 8.57 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 26.84 Million INR | -23.95% |
| 2023 Q1 | -95.35 Million INR | -117.44% |
| 2023 FY | -90.71 Million INR | -814.31% |
| 2023 Q4 | 35.3 Million INR | 609.0% |
| 2023 Q3 | 4.97 Million INR | 113.97% |
| 2023 Q2 | -35.64 Million INR | 62.62% |
| 2022 Q3 | 4.25 Million INR | -80.88% |
| 2022 FY | 12.7 Million INR | -93.54% |
| 2022 Q4 | -43.85 Million INR | -1130.4% |
| 2022 Q1 | 30.03 Million INR | -55.11% |
| 2022 Q2 | 22.26 Million INR | -25.89% |
| 2021 Q2 | 45.28 Million INR | 2.54% |
| 2021 Q4 | 66.91 Million INR | 66.36% |
| 2021 Q1 | 44.15 Million INR | 104.99% |
| 2021 Q3 | 40.22 Million INR | -11.17% |
| 2021 FY | 196.57 Million INR | -29.72% |
| 2020 Q1 | 82.95 Million INR | 64.14% |
| 2020 FY | 279.7 Million INR | 238.94% |
| 2020 Q3 | 64.34 Million INR | -41.97% |
| 2020 Q4 | 21.54 Million INR | -66.52% |
| 2020 Q2 | 110.87 Million INR | 33.65% |
| 2019 FY | 82.52 Million INR | 202.76% |
| 2019 Q1 | 7.39 Million INR | 112.31% |
| 2019 Q4 | 50.54 Million INR | 206.06% |
| 2019 Q2 | 8.07 Million INR | 9.28% |
| 2019 Q3 | 16.51 Million INR | 104.39% |
| 2018 FY | -80.3 Million INR | -140.38% |
| 2018 Q4 | -60.07 Million INR | -35.92% |
| 2018 Q3 | -44.19 Million INR | -355.78% |
| 2018 Q2 | 17.28 Million INR | 158.57% |
| 2018 Q1 | 6.68 Million INR | -78.13% |
| 2017 Q3 | 59.79 Million INR | -10.74% |
| 2017 Q2 | 66.98 Million INR | 61.18% |
| 2017 FY | 198.89 Million INR | -10.71% |
| 2017 Q1 | 41.56 Million INR | -36.17% |
| 2017 Q4 | 30.55 Million INR | -48.9% |
| 2016 Q2 | 51.48 Million INR | 12.83% |
| 2016 Q1 | 45.62 Million INR | -17.56% |
| 2016 Q4 | 65.11 Million INR | 6.84% |
| 2016 FY | 222.75 Million INR | 38.93% |
| 2016 Q3 | 60.94 Million INR | 18.37% |
| 2015 Q1 | 30.52 Million INR | -12.63% |
| 2015 Q2 | 51.02 Million INR | 67.15% |
| 2015 FY | 160.33 Million INR | 161.07% |
| 2015 Q4 | 55.34 Million INR | 45.77% |
| 2015 Q3 | 37.96 Million INR | -25.59% |
| 2014 Q2 | 20.05 Million INR | 1087.98% |
| 2014 Q3 | 8.44 Million INR | -57.88% |
| 2014 FY | 61.41 Million INR | 302.07% |
| 2014 Q4 | 34.93 Million INR | 313.57% |
| 2014 Q1 | -2.03 Million INR | -105.21% |
| 2013 Q1 | -58.65 Million INR | -707.14% |
| 2013 Q2 | -9.69 Million INR | 83.48% |
| 2013 FY | -30.39 Million INR | 74.24% |
| 2013 Q4 | 38.95 Million INR | 3987.92% |
| 2013 Q3 | -1 Million INR | 89.66% |
| 2012 Q1 | -60.26 Million INR | -212.87% |
| 2012 FY | -117.99 Million INR | -1962.28% |
| 2012 Q4 | 9.66 Million INR | 138.64% |
| 2012 Q3 | -25 Million INR | 41.02% |
| 2012 Q2 | -42.38 Million INR | 29.67% |
| 2011 FY | 6.33 Million INR | -69.66% |
| 2011 Q4 | -19.26 Million INR | -1017.29% |
| 2011 Q3 | 2.1 Million INR | 0.0% |
| 2010 FY | 20.88 Million INR | 14.56% |
| 2009 FY | 18.23 Million INR | 43.72% |
| 2008 FY | 12.68 Million INR | 47.88% |
| 2007 FY | 8.57 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 101.473% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 100.286% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 101.927% |
| Granules India Limited | 4.05 Billion INR | 102.238% |
| Indoco Remedies Limited | 984.6 Million INR | 109.214% |
| Achyut Healthcare Limited | 5.73 Million INR | 1682.641% |
| Ajanta Pharma Limited | 8.16 Billion INR | 101.111% |
| Alkem Laboratories Limited | 17.95 Billion INR | 100.505% |
| Alpa Laboratories Limited | 167.76 Million INR | 154.074% |
| Brooks Laboratories Limited | -195.91 Million INR | 53.697% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 105.617% |
| Bajaj HealthCare Limited | -837.93 Million INR | 89.174% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 112.023% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 100.163% |
| Eris Lifesciences Limited | 3.91 Billion INR | 102.314% |
| FDC Limited | 3.05 Billion INR | 102.972% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 99.396% |
| Gufic Biosciences Limited | 861.35 Million INR | 110.532% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 102.155% |
| Ipca Laboratories Limited | 5.47 Billion INR | 101.657% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 140.385% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 54.017% |
| Lasa Supergenerics Limited | -217.3 Million INR | 58.254% |
| Laurus Labs Limited | 1.6 Billion INR | 105.65% |
| Lupin Limited | 19.14 Billion INR | 100.474% |
| Mankind Pharma Limited | 19.12 Billion INR | 100.474% |
| Medicamen Biotech Limited | 109.31 Million INR | 182.991% |
| Medico Remedies Limited | 82.9 Million INR | 209.418% |
| Megasoft Limited | -127.46 Million INR | 28.83% |
| NATCO Pharma Limited | 13.88 Billion INR | 100.653% |
| Piramal Pharma Limited | 178.2 Million INR | 150.907% |
| RPG Life Sciences Limited | 876.6 Million INR | 110.349% |
| Sigachi Industries Limited | 571.8 Million INR | 115.865% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 100.095% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 103.021% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 135.836% |
| Unichem Laboratories Limited | -704.74 Million INR | 87.128% |
| Wanbury Limited | 559.56 Million INR | 116.212% |
| Windlas Biotech Limited | 581.87 Million INR | 115.591% |
| ZIM Laboratories Limited | 172.46 Million INR | 152.601% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 100.235% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 97.657% |
| Divi's Laboratories Limited | 16 Billion INR | 100.567% |
| Hester Biosciences Limited | 188.89 Million INR | 148.026% |
| Procter & Gamble Health Limited | 2 Billion INR | 104.514% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 120.172% |
| Bal Pharma Limited | 73.92 Million INR | 222.72% |
| Strides Pharma Science Limited | -706.14 Million INR | 87.153% |
| Venus Remedies Limited | 284.9 Million INR | 131.841% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 104.182% |
| Nectar Lifesciences Limited | 49.95 Million INR | 281.616% |
| Shilpa Medicare Limited | 318.74 Million INR | 128.461% |
| Aarti Drugs Limited | 1.71 Billion INR | 105.292% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 106.748% |
| Suven Life Sciences Limited | -1.05 Billion INR | 91.367% |
| Ind-Swift Limited | 142.31 Million INR | 163.745% |
| Valiant Laboratories Limited | 3.19 Million INR | 2938.454% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 101.642% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 98.401% |
| Themis Medicare Limited | 435.23 Million INR | 120.843% |
| Hikal Limited | 696.02 Million INR | 113.034% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 100.548% |
| Sequent Scientific Limited | -358.69 Million INR | 74.709% |
| Novartis India Limited | 851.9 Million INR | 110.649% |
| Wockhardt Limited | -4.63 Billion INR | 98.041% |
| Jubilant Pharmova Limited | 771 Million INR | 111.766% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 1379.146% |
| Neuland Laboratories Limited | 3 Billion INR | 103.023% |
| Morepen Laboratories Limited | 961.59 Million INR | 109.434% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 162.129% |